Exelixis Inc (NAS:EXEL)
$ 21.08 0.17 (0.81%) Market Cap: 6.14 Bil Enterprise Value: 5.33 Bil PE Ratio: 32.78 PB Ratio: 2.92 GF Score: 91/100

Exelixis Inc Investor Briefing to Discuss Data Presented at ESMO 2020 Transcript

Sep 19, 2020 / 08:00PM GMT
Unidentified Participant

Thanks for joining us, ladies and gentlemen. Please welcome, Susan Hubbard.

Susan T. Hubbard
Exelixis, Inc. - EVP of Public Affairs & IR

Hello, everyone, and welcome to the Exelixis Investor Briefing at the ESMO Virtual Congress 2020. I'm Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations for Exelixis.

We are very pleased to have you join us for a review of the CheckMate 9ER trial results, which were just presented a few hours ago in ESMO's presidential symposium session by the principal investigator for the study, Dr. Toni Choueiri of the Dana-Farber Cancer Institute. We have a very prestigious panel of physicians joining Dr. Choueiri today to discuss the results from CheckMate 9ER as well as data from 2 renal cell carcinoma cohorts of COSMIC-021 also being presented at the Congress. Following our panel discussion, we'll have a question-and-answer session where we'll field questions from the audience, which I've already received, so thank you, everybody, for sending your questions in.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot